000898782 000__ 03045cam\a2200469Ia\4500
000898782 001__ 898782
000898782 005__ 20230306150243.0
000898782 006__ m\\\\\o\\d\\\\\\\\
000898782 007__ cr\un\nnnunnun
000898782 008__ 190720s2019\\\\sz\\\\\\o\\\\\000\0\eng\d
000898782 019__ $$a1106162127$$a1107346481
000898782 020__ $$a9783030178321$$q(electronic book)
000898782 020__ $$a3030178323$$q(electronic book)
000898782 020__ $$z9783030178314
000898782 020__ $$z3030178315
000898782 0248_ $$a10.1007/978-3-030-17
000898782 035__ $$aSP(OCoLC)on1108535940
000898782 035__ $$aSP(OCoLC)1108535940$$z(OCoLC)1106162127$$z(OCoLC)1107346481
000898782 040__ $$aEBLCP$$beng$$epn$$cEBLCP$$dGW5XE$$dLQU$$dDCT$$dYDX$$dOCLCF$$dOCLCQ
000898782 049__ $$aISEA
000898782 050_4 $$aRC280.L8
000898782 08204 $$a616.99/42406$$223
000898782 24500 $$aTargeted Therapies for Lung Cancer /$$cRavi Salgia, editor.
000898782 260__ $$aCham :$$bSpringer,$$c2019.
000898782 300__ $$a1 online resource (244 pages)
000898782 336__ $$atext$$btxt$$2rdacontent
000898782 337__ $$acomputer$$bc$$2rdamedia
000898782 338__ $$aonline resource$$bcr$$2rdacarrier
000898782 4901_ $$aCurrent Cancer Research Ser.
000898782 5050_ $$a1. EGFR -- 2. ALK -- 3. ROS1 -- 4. B-RAF -- 5. MET -- 6. HER2 -- 7. NTRK -- 8. SCLC -- 9. Complexities of the Lung Tumor Microenvironment -- 10. KRAS -- 11. Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance.
000898782 506__ $$aAccess limited to authorized users.
000898782 520__ $$aThis book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patients genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
000898782 588__ $$aDescription based on print version record.
000898782 650_0 $$aLungs$$xCancer$$xTreatment.
000898782 650_0 $$aDrug targeting.
000898782 7001_ $$aSalgia, Ravi.
000898782 77608 $$iPrint version:$$aSalgia, Ravi.$$tTargeted Therapies for Lung Cancer.$$dCham : Springer, ©2019$$z9783030178314
000898782 830_0 $$aCurrent cancer research.
000898782 852__ $$bebk
000898782 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-17832-1$$zOnline Access$$91397441.1
000898782 909CO $$ooai:library.usi.edu:898782$$pGLOBAL_SET
000898782 980__ $$aEBOOK
000898782 980__ $$aBIB
000898782 982__ $$aEbook
000898782 983__ $$aOnline
000898782 994__ $$a92$$bISE